Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedence spectroscopy (BIS).

ImpediMed produces a family of FDA-cleared and CE-marked medical devices, including SOZO® for multiple indications, including heart failure, protein calorie malnutrition and lymphedema, sold in select markets globally. ImpediMed’s connected digital health platform and large, attractive and growing markets present an opportunity for continued strong growth through its SOZO SaaS subscription-based business.

AUD $19.07M

Market capitalization

Investor relations


Latest Investors Conference Call

January 2020

Latest Investor Presentation

November 2019

Board Committees
and Charters

Analyst coverage

ImpediMed has market-leading coverage with the following entities:

Canaccord Genuity Morgans Wilson HTM equities research

Share register

ImpediMed Limited is listed on the Australian Stock Exchange (ASX). Trading in its securities is under the ticker code on ASX of “IPD” for ordinary shares.

Share register agent

To update shareholder contact information or submit transfer documents, please contact ImpediMed’s share register service provider:

Ph: 1300-554-474
Fax: +61-2-9287-0303

Locked Bag A14
Sydney South
NSW 1235, Australia

Shareholder services

Shares may be bought on market through any Australian stock broker, or through on-market trades, via a number of international brokerage houses. If you are a potential investor needing information on how to trade in shares through an international brokerage house, please contact:

ImpediMed maintains an active communications program with investors and the market. If you are interested in a presentation, please contact:

Investor Relations Contact: 

Mike Bassett, ImpediMed

+61 4 0743 1432


Media Contact:

Kyahn Williamson, WE Buchan

+61 3 9866 4722